Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0600142 (hot flushes)
 1,242 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

Eighty previously treated postmenopausal women with metastatic breast cancer were randomized to receive fadrozole (CGS 16 949A), a new aromatase inhibitor, 1 or 4 mg orally per day. Seventy eight patients were evaluable for toxicity and response. Only mild to moderate toxicity, namely hot flushes (28%), nausea and vomiting (13%), fatigue (8%) and loss of appetite (5%) occurred. Complete response was documented in 10% and partial response in 13% of patients with 45% having a no change status for at least 2 months. The median time to treatment failure is 4.1 months. The median survival is 23.7 months. The median survival is 23.7 months. The response and survival in patients with estrogen receptor positive and estrogen receptor unknown disease were not significantly different. Neither response nor survival was significantly different between the patients receiving 1 or 4 mg of fadrozole per day. Fadrozole is a well tolerated, effective second line treatment for women with metastatic breast cancer.
J Steroid Biochem Mol Biol 1992 Sep
PMID:Fadrozole hydrochloride, a new nontoxic aromatase inhibitor for the treatment of patients with metastatic breast cancer. 138 48

The authors contend that conclusions regarding the existence of a menopausal syndrome based on clinical trials with oestrogen therapy cannot be generalized to the general population. As an alternative strategy for investigating the nature of the menopausal syndrome the authors performed a factor analysis of the results from a symptom checklist. The list was included in a postal questionnaire sent to a representative sample of 2349 women aged between 45 and 55 years residing in the city of Oslo, Norway. A varimax, rotated five-factor solution yielded the best result both theoretically and empirically. The five factors were labelled as vague somatic complaints, nervousness, mood lability, vasomotor complaints and urogenital complaints. Five variables were constructed on the basis of the factor scores. One-way analysis of variance showed that vasomotor complaints associated with excessive sweating, hot flushes and vaginal dryness, constituted the only variable significantly related to menopausal development. The latter was measured according to time elapsed since the last menstrual period.
Maturitas 1991 Sep
PMID:The menopausal syndrome: a factor analytic replication. 194 27

A total of 2349 Norwegian women aged 45-55 years, were investigated using postal questionnaires. Associations between menopausal development, psychosocial factors and climacteric complaints were analyzed. Factor analysis of 24 climacteric complaints identified five factors (vague somatic complaints, nervous complaints, mood lability, vasomotor and urogenital complaints) which were analyzed in relation to stage of menopausal development and a number of psychosocial variables. Five types of variable contributed to the variance in the five previously identified factors, viz. style of reacting to menstruation earlier in life, mother's climacteric complaints, negative expectations regarding the menopause, social network, sociodemographic factors, and chronological age. Menopausal development played a modest role in explaining the variance in all except vasomotor complaints, the latter being associated with current cigarette smoking. Traditional sex-role identification was associated with nervous complaints. The authors conclude that hot flushes, excessive sweating and vaginal dryness are the only complaints clearly attributable to menopausal development.
Maturitas 1991 Sep
PMID:Psychosocial determinants of climacteric complaints. 194 28

A random probability cluster area sampling of 614 women living in Bangkok was conducted to determine the prevalence of abnormal symptoms related to the menopause. Women interviewed were aged 40 and above currently registered as living in the Bangkok Metropolitan area. Sixty-nine percent of the women interviewed experienced abnormal symptoms. Eighty-two percent of those with abnormal symptoms reported having hot flushes. Palpitation, increased heat intolerance and emotional liability were common symptoms. Minor abnormalities included insomnia, weakness, anxiety and urinary symptoms. Changes related to sexual function were difficult to elicit due to cultural limitations. Economic and cultural factors might play important roles in the way these women perceived symptoms related to the menopause and sought medical assistance.
Maturitas 1991 Sep
PMID:Menopausal symptoms among Thai women in Bangkok. 194 29

The effect transcutaneous oestradiol for four months supplemented by medroxyprogesterone (Perlutex) from the 12th to 26th day of every month was assessed in an open uncontrolled prospective investigation in 34 women with menopausal symptoms and follicle stimulating hormone greater than 40 international units and luteinizing hormone greater than 25 international units. A marked effect was found on sweating and hot flushes and other menopausal complaints as expressed by Kupperman's menopausal index. Serum oestradiol increased during the first two months to follicular phase values and this was followed by an unexplained decrease after the fourth month which did not, however, result in aggravation of the symptoms. No alterations were found in steroid-hormone-binding globulin, lipids and body weight. Whether the patients placed the plasters in the hip or abdominal regions was found to be of no significance. Seventeen patients had no side effects of the treatment. Nine patients had transient skin symptoms which disappeared spontaneously. Five patients had mastalgia which disappeared after reduction of the Perlutex dose. One patient developed metrorrhagia. A total of three patients abandoned the treatment: one on account of skin symptoms, one on account of high blood pressure and a third on account of psychiatric symptoms which were unrelated to the treatment. A total of 28 patients wanted to continue treatment after the fourth month.
Ugeskr Laeger 1990 Sep 03
PMID:[Transcutaneous estradiol treatment in the climacteric]. 240 44

Five out of 6 normally-menstruating women who were treated with a potent gonadotropin-releasing hormone (Gn-RH) agonist in order to achieve medical hypophysectomy developed hot flushes despite having normal oestradiol (E2) levels. The Gn-RH agonist was administered subcutaneously for 6 days and then intranasally for a further 14 days. A dose of 2 mg of E2 benzoate was injected intramuscularly once a week for 2 consecutive weeks. This combined treatment resulted in low peripheral gonadotropin levels but normal serum E2 concentrations. Four (4) women developed mild to moderate hot flushes and there was 1 case of flushes severe enough to necessitate cessation of treatment. The flushes occurred in the second week of Gn-RH analogue treatment when the level of serum luteinizing hormone (LH) was low and the pituitary was unresponsive to provocative tests, despite the fact that the patients' E2 levels were normal (mean 250 +/- 25 pg/ml). It is suggested that neither LH pulsatility nor low peripheral E2 levels are mainly responsible for the development of hot flushes. It is possible that Gn-RH, a hypothalamic decapeptide, may play a major role or act as a mediator in the aetiology of hot flushes.
Maturitas 1989 Sep
PMID:Hot flushes during Gn-RH analogue administration despite normal serum oestradiol levels. 251 68

Long acting D-Trp-6-luteinizing hormone-releasing hormone (LH-RH) microcapsules, 3.2 mg were given monthly, intramuscularly for a period of 6 months to 26 menstruating patients with symptomatic leiomyomas. The patients ages were 22 to 52 years. Five patients (20%) were infertile. Patient evaluation before initiation of treatment included endometrial biopsy, ultrasonic measurements of uterine and tumor volumes, and bone-mineral density. The patients were periodically followed hormonally and ultrasonographically. A statistically significant reduction in uterine and tumor volumes (maximal after 4 months of treatment) was observed in all the patients except one. Two patients discontinued the treatment after 2 months, preferring surgery. A nonsignificant decrease in the mean bone-mineral density was noted after completion of therapy. Minor side effects such as hot flushes, vaginal dryness, backache, vaginal spotting, and nervousness, were encountered frequently, disappearing within 6 weeks after the last injection. A significant increase in uterine and myoma volume was noted in all the patients at 3 months after treatment.
Fertil Steril 1989 Sep
PMID:D-Trp-6-luteinizing hormone-releasing hormone microcapsules in the treatment of uterine leiomyomas. 252 76

The induction of a state of hypo-oestrogenism has been found to be effective in the treatment of endometriosis. Continued administration of agonistic analogues of luteinizing hormone-releasing hormone (LHRH) results in the normal menstruating female developing normogonadotrophic-amenorrhoea with reduced circulating levels of oestradiol-17B, often within the menopausal range. Uncontrolled studies reported the efficacy of LHRH analogues in patients with mild, moderate and even severe endometriosis (American Fertility Society classification) following 6 months therapy. A number of large multi-centre randomized open or double blind trials comparing various LHRH analogues against danazol are currently underway. Published results available to date indicate that LHRH analogues and danazol are equally effective at reducing the symptoms of endometriosis and inducing complete or partial resolution of endometriotic deposits. Side-effects are, however, more severe with danazol therapy. The side-effects experienced with LHRH analogues are those expected from an induced state of hypo-oestrogenism--hot flushes, dry vagina, headaches, superficial dyspareunia--but are well tolerated by patients. The alterations observed in bone and calcium metabolism are comparable to those in the menopause--increased Ca++ loss and reversible loss of trabecular bone density have been reported. These effects may limit the duration and/or frequency of LHRH analogue treatment regimens. The valuable role of LHRH analogues in the treatment of endometriosis has been established and, as newer formulations become available, they are likely to play an increasingly important part in patient management.
Baillieres Clin Obstet Gynaecol 1988 Sep
PMID:LHRH analogues in the treatment of endometriosis--comparative results with other treatments. 306 68

A telephone survey of a random sample of 594 perimenopausal women was done to study the prevalence of hot flashes, use of estrogen, age of menopause onset, and, among those subjects experiencing hot flashes, the frequency of occurrence and number of years of hot flashes. The prevalence of hot flashes was 88%. Surgical menopause women had a prevalence rate of 92% and had the highest estrogen utilization rate. The median age of onset for natural menopause women was 49 years. The frequency of occurrence and number of years of hot flash experience was variable across all groups.
Res Nurs Health 1985 Sep
PMID:The prevalence of hot flash and associated variables among perimenopausal women. 385 61

Twenty post-menopausal women (10 natural and 10 surgical menopauses) with climateric manifestations consisting mainly in hot flushes were given veralipride. Overall satisfactory results obtained in two-thirds of cases evidence the value of tis non-hormonal therapy, especially in cases of natural menopause which responded consistently. Clinical tolerance of veralipride proved satisfactory. Biological investigations (total and differential blood cell counts, glucid and lipid metabolism, BUN, transaminases) before and after three twenty-day courses of veralipride showed no modifications. Hormonal assays done in four patients showed no action of veralipride on FSH and LH.
Sem Hop 1983 Sep 01
PMID:[Veralipride and menopause]. 631 85


1 2 3 4 5 6 7 Next >>